Aegerion Pharmaceuticals Announces Final Lomitapide (AEGR-733) Phase II Data

Aegerion Pharmaceuticals Announces Interim Lomitapide (AEGR-733) Phase III Data Demonstrates Significant Lowering of LDL Cholesterol with Promising Hepatic Safety Profile
  Aegerion Luncheon Symposium as presented at the International Society of Atherosclerosis conference
Boston, MA
June 16, 2009
   
 

About Aegerion Pharmaceuticals

Aegerion Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of pharmaceuticals to treat cardiovascular (CV) and  metabolic disease.

 

   

 

   

        Copyright © Aegerion Pharmaceuticals, Inc. All rights reserved.

 

        Aegerion Pharmaceuticals, Inc. CenterPointe IV, 1140 Route 22 East, Suite 304, Bridgewater, NJ 08807 [T: 908-707-2100 F: 908-541-1155]

Overview
Mission and Values
Senior Management Team
Board of Directors
Scientific Advisory Board
About MTPI
About Technology 2
Publications
Current
Press Release Archive
Article Archive
Current
Press Release Archive
Article Archive